Prevention of recurrence of spontaneous subarachnoid haemorrhage by tranexamic acid.
Tranexamic acid as an antifibrinolytic agent has been investigated in a controlled study in patients with recent subarachnoid haemorrhage. It is concluded that tranexamic acid improves neither rebleeding rates, nor mortality. Predominantly thrombotic complications have been noted as a more serious side effect of tranexamic acid.
D000328:Adult; D000368:Aged; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D013345:Subarachnoid Hemorrhage / Q000401:mortality / Q000517:prevention & control*; D013924:Thrombophlebitis / Q000139:chemically induced; D014148:Tranexamic Acid / Q000009:adverse effects / Q000627:therapeutic use*
D003509:Cyclohexanecarboxylic Acids; D014148:Tranexamic Acid